TEV-48574 Dose Regiment B

Phase 2

Teva

TEV-48574 Dose Regiment B is one of 22 therapeutic programs targeting Crohn Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Crohn DiseaseActive, not recruiting

Crohn DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Crohn Disease

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Approved

4 2

Omvoh

Eli Lilly

Approved

2 3

Stelara

Johnson & Johnson

Phase 3

4 4

Skyrizi

AbbVie

Phase 3

1 5

Entyvio

Takeda

Phase 2

1 6

Medrol

Pfizer

Phase 2

1 7

Rituxan

Roche

Phase 2

1 8

Clolar

GGenzyme, a Sanofi Company

Phase 2

1 9

Kepivance

SSwedish Orphan Biovitrum

Phase 2

1 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Active, not recruiting

Crohn Disease

NCT05668013

Clinical

Trials by Indication[1]

Crohn Disease1 trial

A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)

Active, not recruiting· Teva logo

Teva·Phase 2·NCT05668013·247 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TEV-48574 Dose Regiment B. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TEV-48574 Dose Regiment B. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Teva

TEV-48574 Dose Regiment B

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Crohn Disease1 trial

References

Drug Info

Quick Facts

Related News